All articles by Manish Kumar

Manish Kumar

Otsuka gains Asia-Pacific rights for Ionis’ HAE candidate donidalorsen

Following the expanded agreement, Otsuka Pharmaceutical will oversee the territory-specific development, regulatory filings, and commercialisation for donidalorsen in Asia Pacific as well as Europe

Belharra and Sanofi ink immunology drug discovery deal worth up to $700m

Under the partnership, the California-based Belharra Therapeutics and French pharma major Sanofi will advance the discovery of novel small molecule therapeutics for immunological diseases

Clover announces positive preliminary Phase 1 results for bivalent RSV vaccine candidate SCB-1019 in older adults

Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralizing antibody titers in older adults up to approximately 7,900 IU/mL (up to 8-fold increase) and approximately 46,700 IU/mL (up to 11-fold increase), respectively

iTeos and GSK start Phase 3 NSCLC trial of belrestotug and dostarlimab

The combination will be evaluated against placebo plus pembrolizumab in patients with previously untreated, unresectable, locally advanced, or metastatic PD-L1 selected NSCLC

FDA approves AstraZeneca’s Imfinzi, chemo combo for dMMR endometrial cancer

In the DUO-E trial, Imfinzi in combination with carboplatin and paclitaxel resulted in a 58% reduction in the risk of disease progression or death compared to chemotherapy alone

Takeda announces Phase 3 topline results for Soticlestat (TAK-935) in patients with dravet syndrome and lennox-gastaut syndrome

SKYLINE Study in Dravet Syndrome Narrowly Missed its Primary Endpoint of Reduction in Convulsive Seizure Frequency and Showed Clinically Meaningful and Nominally Significant Effects in Multiple Key Secondary Efficacy Endpoints

Roche’s Columvi shows extended survival rate in Phase 3 DLBCL study

In the trial, patients treated with Columvi with GemOx experienced a significant extension in survival, showing a 41% reduction in the risk of death compared to those receiving R-GemOx

Amgen’s Blincyto gets FDA approval for acute lymphoblastic leukaemia

The approval was based on results from the Phase 3 E1910 trial in which the addition of Blincyto to multiphase consolidation chemotherapy improved OS compared to chemotherapy alone

Enveda Biosciences announces $55m in new funding to accelerate platform and advance multiple candidates to clinical trials

The closing of this Series B2 round brings the total capital that Enveda has raised to $230m

Suven Pharmaceuticals signs deal to acquire CDMO Sapala Organic

Under the deal, Suven will initially acquire a 67.5% equity stake in Sapala Organics in FY 2024-2025 followed by acquisition of remaining equity stake in FY 2026-2027 to secure the full ownership